REGULATED PRESS RELEASE published on 06/04/2025 at 07:00, 9 months 20 days ago Biophytis announces its participation in the BIO International Convention from June 16 to 19 Biophytis announces participation in BIO International Convention from June 16 to 19, 2025 in Boston, USA. Focus on drug candidate BIO101 and potential partnerships Biophytis Biotechnology Partnerships BIO International Convention Drug Candidate
REGULATED PRESS RELEASE published on 06/04/2025 at 07:00, 9 months 20 days ago Biophytis annonce sa participation à la BIO International Convention du 16 au 19 juin Biophytis participera à la BIO International Convention du 16 au 19 juin 2025 à Boston, USA, pour présenter ses avancées et son candidat médicament BIO101 Biophytis Biotechnologie Boston BIO International Convention Maladies Liées À L'âge
BRIEF published on 05/30/2025 at 22:05, 9 months 24 days ago Biophytis reporte la publication de ses comptes annuels 2024 Biophytis Assemblée Générale Comptes Annuels Audit Report
BRIEF published on 05/30/2025 at 22:05, 9 months 24 days ago Biophytis Delays 2024 Annual Financial Report Publication Financial Statements Biophytis Shareholder Meeting Age-related Diseases Audit Delay
REGULATED PRESS RELEASE published on 05/30/2025 at 22:00, 9 months 24 days ago Information sur les comptes annuels Biophytis reporte la publication des comptes annuels 2024 en raison de complications techniques dans le processus d'audit. L'assemblée générale des actionnaires est également repoussée Biophytis Assemblée Générale Comptes Annuels Audit Report
REGULATED PRESS RELEASE published on 05/30/2025 at 22:00, 9 months 24 days ago Information on the Annual Financial Statements Biophytis postpones the publication of its 2024 annual financial statements due to technical complications in the audit process. The Company aims to complete the audit by the end of June 2025 Biophytis Audit Postponement 2024 Annual Financial Statements Technical Complications
PRESS RELEASE published on 05/30/2025 at 21:59, 9 months 24 days ago Information sur les comptes annuels Biophytis reporte la publication de ses comptes annuels 2024 en raison de complications techniques dans l'audit. L'assemblée générale est également reportée. La société se concentre sur le développement de traitements pour les maladies liées à l'âge Biophytis Développement Comptes Annuels Report Maladies Liées À L'âge
PRESS RELEASE published on 05/30/2025 at 21:59, 9 months 24 days ago Information on the Annual Financial Statements Biophytis postpones 2024 annual financial statements publication due to technical audit issues, reschedules General Meeting of shareholders following legal procedures Shareholders Financial Statements Biophytis Meeting Audit
BRIEF published on 05/15/2025 at 07:05, 10 months 9 days ago Biophytis présente une avancée dans le traitement de l'obésité à l'ECO 2025 Biophytis Essai Clinique BIO101 Obésité GLP-1
BRIEF published on 05/15/2025 at 07:05, 10 months 9 days ago Biophytis Unveils Promising Obesity Treatment at ECO 2025 Biophytis Clinical Trials Obesity Treatment BIO101 ECO 2025
Published on 03/24/2026 at 07:00, 44 minutes ago Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 44 minutes ago Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/23/2026 at 22:40, 9 hours 4 minutes ago Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 9 hours 14 minutes ago Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp
Published on 03/24/2026 at 07:30, 14 minutes ago Drägerwerk AG & Co. KGaA: Dräger with good order development, record net sales and significant increase in net profit in fiscal year 2025 – third dividend increase in a row
Published on 03/24/2026 at 07:23, 20 minutes ago INDUS confirms a solid financial year 2025 – Proposed dividend of EUR 1.30 exceeds previous year
Published on 03/24/2026 at 07:00, 43 minutes ago After strong fourth quarter, INFICON closes 2025 at record sales level
Published on 03/24/2026 at 07:00, 43 minutes ago Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achieved
Published on 03/24/2026 at 07:30, 14 minutes ago Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 14 minutes ago Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 12 hours 36 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 19:08, 12 hours 36 minutes ago Déclaration de rachats d'actions effectués par la Compagnie de Saint-Gobain entre le 16 et le 20 mars 2026
Published on 03/23/2026 at 18:37, 13 hours 7 minutes ago ALTAREA : Déclaration d’opérations sur actions propres
